BR112022016216A2 - Anticorpos anti-il-2 modificados - Google Patents

Anticorpos anti-il-2 modificados

Info

Publication number
BR112022016216A2
BR112022016216A2 BR112022016216A BR112022016216A BR112022016216A2 BR 112022016216 A2 BR112022016216 A2 BR 112022016216A2 BR 112022016216 A BR112022016216 A BR 112022016216A BR 112022016216 A BR112022016216 A BR 112022016216A BR 112022016216 A2 BR112022016216 A2 BR 112022016216A2
Authority
BR
Brazil
Prior art keywords
antibodies
modified
modified anti
subsets
infection
Prior art date
Application number
BR112022016216A
Other languages
English (en)
Inventor
Amit Inbar
Levin Itay
Nimrod Guy
Fischman Sharon
Barak Fuchs Reut
Strajbl Marek
Wyant Timothy
Zhenin Michael
Bluvshtein Yermolaev Olga
Sasson Yehezkel
Grossman Noam
Levitin Natalia
Ofran Yanay
Original Assignee
Aulos Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aulos Bioscience Inc filed Critical Aulos Bioscience Inc
Publication of BR112022016216A2 publication Critical patent/BR112022016216A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTICORPOS ANTI-IL-2 MODIFICADOS. Anticorpos anti-IL-2 modificados com sequências de aminoácidos modificadas são descritos na presente invenção. Os anticorpos modificados confeririam especificidade de ligação ao receptor modificada a um complexo de anticorpos anti-IL-2-IL2, inibindo a ligação de IL-2 a CD25. Os anticorpos anti-IL2 modificados facilitariam a expansão de subconjuntos de células imunes efetoras e diminuiriam os efeitos indesejáveis causados por IL-2. Assim, os anticorpos anti-IL-2 modificados seriam úteis no tratamento de doenças, tais como câncer e infecção.
BR112022016216A 2020-02-16 2021-02-15 Anticorpos anti-il-2 modificados BR112022016216A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977292P 2020-02-16 2020-02-16
US202163139315P 2021-01-20 2021-01-20
PCT/IB2021/051267 WO2021161287A2 (en) 2020-02-16 2021-02-15 Engineered anti-il-2 antibodies

Publications (1)

Publication Number Publication Date
BR112022016216A2 true BR112022016216A2 (pt) 2023-02-28

Family

ID=77295172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016216A BR112022016216A2 (pt) 2020-02-16 2021-02-15 Anticorpos anti-il-2 modificados

Country Status (12)

Country Link
US (3) US20230085471A1 (pt)
EP (1) EP4103607A4 (pt)
JP (2) JP7292526B2 (pt)
KR (2) KR20240014590A (pt)
CN (2) CN115397852B (pt)
AU (2) AU2021221287B2 (pt)
BR (1) BR112022016216A2 (pt)
CA (1) CA3166139A1 (pt)
IL (2) IL295210B2 (pt)
MX (1) MX2022010034A (pt)
WO (1) WO2021161287A2 (pt)
ZA (1) ZA202209060B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022332510A1 (en) * 2021-08-25 2024-02-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing fusion protein
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02209898A (ja) * 1988-10-31 1990-08-21 Takeda Chem Ind Ltd 修飾インターロイキン―２
WO2008070179A2 (en) * 2006-12-06 2008-06-12 Monsanto Technology, Llc Genes and uses for plant improvement
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
AU2013388126B2 (en) * 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
CN106604932A (zh) 2014-07-10 2017-04-26 诺华公司 人白细胞介素‑2的免疫刺激单克隆抗体
EP3307779A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
JP6908591B2 (ja) 2015-08-06 2021-07-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｉｌ２ｒベータ／共通ガンマ鎖抗体
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
EP3630825B1 (en) * 2017-05-25 2024-02-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
WO2019168791A2 (en) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells

Also Published As

Publication number Publication date
MX2022010034A (es) 2022-12-13
AU2021221287B2 (en) 2023-10-05
NZ791361A (en) 2023-08-25
KR20240014590A (ko) 2024-02-01
EP4103607A4 (en) 2023-12-20
US20230085471A1 (en) 2023-03-16
ZA202209060B (en) 2023-12-20
CA3166139A1 (en) 2021-08-19
CN115397852B (zh) 2023-08-11
JP2023506093A (ja) 2023-02-14
AU2021221287A1 (en) 2022-08-25
KR102627471B1 (ko) 2024-01-18
WO2021161287A2 (en) 2021-08-19
JP7292526B2 (ja) 2023-06-16
CN117143233A (zh) 2023-12-01
US11851485B2 (en) 2023-12-26
IL308185A (en) 2024-01-01
AU2023266270A1 (en) 2023-12-07
IL295210B1 (en) 2023-12-01
EP4103607A2 (en) 2022-12-21
IL295210B2 (en) 2024-04-01
US20240092888A1 (en) 2024-03-21
KR20220143716A (ko) 2022-10-25
JP2023113807A (ja) 2023-08-16
CN115397852A (zh) 2022-11-25
WO2021161287A3 (en) 2021-09-16
IL295210A (en) 2022-10-01
US20230203152A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
BR112022016216A2 (pt) Anticorpos anti-il-2 modificados
BR112017003108A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
PH12019502561A1 (en) Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
BR112018067696A2 (pt) membros de ligação à pd-l1
MX2021010320A (es) Administracion de biomoleculas a celulas mononucleares de sangre periferica (pbmc) para modificar una respuesta inmunitaria.
BR112017008693A2 (pt) célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
MD3353212T2 (ro) Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
BR112016024579A2 (pt) métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
BRPI0721003B8 (pt) composições e uso
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
AR059604A1 (es) Anticuerpos contra il- 22 humana y usos para los mismos
BRPI0512017A (pt) dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas
CO2020014663A2 (es) Anticuerpo de repetición de dipéptidos (dpr) anti (poli-ga) derivado de humanos
BR112021020426A2 (pt) Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
BR112022009100A2 (pt) Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
BR112023011658A2 (pt) Anticorpo de domínio único anti-gucy2c (sdab), receptor de antígeno quimérico (car), ácido nucleico isolado, vetor, célula efetora imune manipulada, composição farmacêutica e método de tratamento de uma doença ou distúrbio em um sujeito
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
BR112021026364A2 (pt) Antígenos de câncer e métodos
BR112022000020A2 (pt) Antígenos de câncer inovadores e métodos
EA202091732A1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения
CR20230523A (es) Anticuerpos anti-cd122 y usos de estos